NEWARK, Del., Sept. 24, 2026 — According to Future Market Insights, the global radiotherapy support nutrition market is projected to increase from USD 260.4 million in 2026 to USD 594.3 million by 2036, expanding at a CAGR of 8.6% during the forecast period. The market was valued at USD 239.8 million in 2025. Demand is being supported by treatment-related swallowing difficulty, appetite loss, taste changes, and gastrointestinal symptoms that can make conventional food intake more difficult during radiotherapy.
👉 Get Detailed Market Forecasts, Competitive Benchmarking, and Pricing Trends:
https://www.futuremarketinsights.com/reports/sample/rep-gb-35466
Global Segment Leaders
- Product Type – High-Protein ONS: 40.6% share in 2026. These products can supplement protein and energy when patients require additional nutrition but can still consume products orally.
- Radiation Site – Head & Neck: 41.7% share in 2026. Treatment involving areas directly associated with eating and swallowing can create a greater need for concentrated, texture-adapted, or enteral nutrition.
- Phase – During Treatment: 49.3% share in 2026. Nutrition problems can be identified and addressed while radiotherapy is ongoing, supporting product starts and adjustments during active treatment.
- End User – Cancer Centers: 47.1% share in 2026. Cancer centers bring oncology and nutrition teams together, allowing nutritional needs to be assessed and products adjusted during treatment.
- Sales Channel – Hospital Pharmacy: 40.2% share in 2026. Hospital pharmacies can support formulary-based and medically supervised nutrition use before patients transition toward retail or home channels.
Country-Level Performance
| Country | CAGR | Key Growth Driver |
| South Korea | 8.7% | Cancer-center nutrition services and continued investment in radiotherapy infrastructure support closer integration of nutrition care with treatment. |
| USA | 8.1% | Established clinical nutrition channels support oral supplementation, while enteral nutrition creates additional demand where patients meet coverage requirements. |
| UK | 7.7% | Dietitian-led NHS pathways support structured nutritional intervention during and after radiotherapy. |
| Germany | 7.3% | Updated oncology nutrition guidance emphasizes prevention of undernutrition and coordinated care across the disease course. |
| Japan | 6.5% | Rehabilitation and swallowing support, together with food texture and sensory acceptance, influence nutrition product selection during recovery. |
The five profiled countries are forecast to expand at between 6.5% and 8.7% CAGR from 2026 to 2036.
Regional Context
South Korea records the highest CAGR among the profiled countries at 8.7%, followed by the USA at 8.1%. The UK and Germany are projected to expand at 7.7% and 7.3%, respectively, while Japan records a 6.5% CAGR.
The report covers North America, Latin America, Western Europe, Eastern Europe, East Asia, South Asia and Pacific, and the Middle East and Africa. The detailed regional assessment includes markets across the United States and Canada; Brazil, Mexico, Argentina, and Chile; major Western and Eastern European markets; China, Japan, and South Korea; India, ASEAN, and Australia and New Zealand; and GCC countries, South Africa, Türkiye, and Israel.
Market Drivers, Restraints and Opportunities
Radiotherapy-related difficulty with swallowing, taste, appetite, and gastrointestinal tolerance is increasing the need for concentrated oral and enteral nutrition. Patients may progress from conventional food supplemented with oral nutrition products to more concentrated formulas, texture-adapted products, and eventually tube feeding as intake becomes more difficult.
Product tolerance remains a consideration. Taste, thickness, serving volume, stomach tolerance, and swallowing difficulty can influence whether a patient continues using a product. Reimbursement requirements and institutional formularies can also affect adoption, particularly when care moves toward enteral feeding.
An opportunity exists for suppliers to develop portfolios that support multiple stages of the treatment and recovery pathway. Connecting oral supplementation with texture-adapted products, tube feeding, and post-discharge replenishment can help maintain continuity as patient requirements change.
👉 Access the Complete Report in PDF Format:
https://www.futuremarketinsights.com/reports/brochure/rep-gb-35466
Competitive Landscape
The competitive landscape includes Nestlé Health Science, Danone Nutricia, Abbott, Fresenius Kabi, Lyons Health Labs, Medtrition, Victus, and B. Braun. The report identifies broad specialized-nutrition platforms, clinical enteral and feeding-route specialists, and focused suppliers serving concentrated protein, dysphagia, gastrointestinal tolerance, and other specific nutrition requirements.
Key developments include:
- July 2025: Danone completed its acquisition of a majority stake in Kate Farms, expanding its specialized nutrition presence across hospital, home, online, and retail settings.
- March 2025: Medtrition launched ProSource Cup and ProSource Cup Plant, offering 20 g of complete protein in compact formats intended for oral and tube-fed patients.
- June 2026: B. Braun updated its catalog listing for Nutricomp Drink 2.0 kcals fibre, a high-energy medical nutrition product for disease-related malnutrition.
The report’s competitive benchmarking evaluates companies on high-protein/calorie-dense oral support, escalation-path coverage, care-setting continuity, and geographic reach.
Analyst Perspective
“Radiotherapy support nutrition works best commercially when a supplier can stay relevant as the patient’s condition changes. A high-protein product alone is not enough. The stronger position comes from supporting the move from oral nutrition to texture-modified products or enteral feeding, and then making sure patients can continue using suitable products after leaving the cancer center.”
— Anurag Sharma, Principal Consultant, Future Market Insights
About Future Market Insights
Future Market Insights (FMI) is a leading provider of market research and consulting services, offering syndicated and customized research across industries including healthcare, pharmaceuticals, and food & beverage.
Access Full Report: https://www.futuremarketinsights.com/reports/radiotherapy-support-nutrition-market
Related Reports:
- Prospera Donor-Derived Cell-Free DNA Transplant Monitoring Market – https://www.futuremarketinsights.com/reports/prospera-donor-derived-cell-free-dna-transplant-monitoring-market
- Outpatient Chemotherapy-Free Cancer Treatment Market – https://www.futuremarketinsights.com/reports/outpatient-chemotherapy-free-cancer-treatment-market
- Genome Engineering Organ Transplant Market – https://www.futuremarketinsights.com/reports/genome-engineering-organ-transplant-market
About Future Market Insights (FMI)
Future Market Insights (FMI) is a global market intelligence and consulting firm providing comprehensive market research, competitive intelligence, and strategic business insights across industries. The firm delivers detailed forecasts, technology analysis, and data-driven recommendations that support informed decision-making for manufacturers, investors, distributors, and policymakers worldwide.
For Press & Corporate Inquiries
Rahul Singh
AVP – Marketing and Growth Strategy
Future Market Insights, Inc.
+91 8600020075
For Sales – [email protected]
For Media – [email protected]
For Web – https://www.futuremarketinsights.com
